Where does National Health Investors's balance sheet data come from?

Every line is extracted from National Health Investors's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

National Health Investors NHI Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$19.62M-26.0%	$26.5M+7.7%	$24.62M+27.6%	$19.29M-48.4%
Restricted cash	$0-100%	$2.21M-2.5%	$2.27M+2.0%	$2.23M+7.3%
Assets held for sale	$3.56M—	$0-100%	$5M-88.4%	$43.3M-34.8%
Tenant receivables	$78.89M-9.5%	$87.15M+2.9%	$84.71M+10.2%	$76.9M-20.1%
Property and equipment, net	$2.47B+11.9%	$2.21B+4.9%	$2.11B-0.5%	$2.12B-8.6%
Land	$221.66M+15.5%	$191.91M+6.2%	$180.75M+1.8%	$177.53M-4.9%
Construction in progress	$18.21M+72.4%	$10.57M+78.7%	$5.91M+76.4%	$3.35M+616%
Accumulated depreciation	$821.98M+10.7%	$742.3M+10.3%	$673.28M+10.1%	$611.69M+6.1%
Other non-current assets	$17.76M-22.0%	$22.75M-5.4%	$24.06M+45.1%	$16.59M-21.2%
Equity method investments	——	——	——	——
Gross loans	$203.3M-24.4%	$268.93M+9.6%	$245.27M+5.2%	$233.14M-22.3%
Allowance for credit losses	$15.4M-24.0%	$20.25M+30.8%	$15.48M+0.9%	$15.34M—
Investment properties, at cost	——	——	——	——
Total assets	$2.8B+7.0%	$2.61B+5.1%	$2.49B-0.8%	$2.51B-11.7%
Deferred revenue	$5M+16.8%	$4.28M-28.8%	$6.01M+18.9%	$5.05M-11.8%
Current portion of long-term debt	——	——	——	——
Operating lease liabilities, current	$1.7M0.0%	$1.7M-0.3%	$1.71M-1.1%	$1.72M—
Accrued interest	——	——	——	——
Dividends payable	$44.44M+8.1%	$41.12M+5.2%	$39.07M0.0%	$39.05M-5.4%
Long-term debt	$1.16B+1.6%	$1.15B+1.0%	$1.14B-1.1%	$1.15B-7.7%
Operating Lease Liabilities (Total)	$1.7M0.0%	$1.7M-0.3%	$1.71M-1.1%	$1.72M—
Total liabilities	$1.26B+2.3%	$1.23B+1.2%	$1.21B-0.3%	$1.22B-7.9%
Common stock	100M+21,782%	457K+5.3%	434K0.0%	434K-5.4%
Additional paid-in capital	$1.92B+10.7%	$1.74B+8.3%	$1.6B+0.3%	$1.6B+0.5%
Retained earnings	$2.75B+5.5%	$2.6B+5.6%	$2.47B+5.8%	$2.33B—
Redeemable noncontrolling interests	$10.2M+4.1%	$9.79M+1.4%	$9.66M-1.7%	$9.83M—
Noncontrolling interests	$8.17M-8.4%	$8.91M-14.6%	$10.44M+5.9%	$9.86M-0.4%
Distributions in excess of accumulated earnings	$3.15B+5.8%	$2.98B+5.6%	$2.82B+5.9%	$2.66B—
Total stockholders' equity	$1.52B+11.3%	$1.37B+9.0%	$1.25B-1.3%	$1.27B-15.7%
Total liabilities and stockholders' equity	$2.8B+7.0%	$2.61B+5.1%	$2.49B-0.8%	$2.51B-11.7%
Operating Lease Income - 2022 (Lessor)	——	——	——	——
Operating Lease Income - 2025 (Lessor)	——	——	——	——
Operating Lease Receivables (Current)	——	——	——	——
Equity Method Investment Basis Difference	——	——	——	-$5M0.0%
Net Investment in Lease	——	——	——	——
Private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4	$203.3M-24.4%	$268.93M+9.6%	$245.27M+5.2%	$233.14M—
Buildings, building improvements and intangible assets	$3.06B—	——	——	——
Investments	——	——	——	——
Other Assets	$17.76M-22.0%	$22.75M-5.4%	$24.06M+45.1%	$16.59M-21.2%
Property, plant and equipment at cost	$3.3B+11.6%	$2.95B+6.2%	$2.78B+1.8%	$2.73B-5.7%
Operating Lease Income - 2026 (Lessor)	——	——	——	——
Operating Lease Income - 2027 (Lessor)	——	——	——	——
Operating Lease Income - 2028 (Lessor)	——	——	——	——
Operating Lease Income - Thereafter (Lessor)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Debt Instrument Face Amount	$204M-38.4%	$331.2M+35.2%	$245M+483%	$42M—
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2025	——	——	——	——
Debt Maturity - 2026	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Debt Maturity - Over 10 Years	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$9.84M+9.2%	$9.02M+1.2%	$8.91M+4.4%	$8.54M+37.0%
Accounts payable, accrued expenses, and other liabilities (includes VIE balances of $159 and $183)	$43.73M+15.8%	$37.76M+10.1%	$34.3M+32.4%	$25.91M+11.8%
Total debt	$1.17B+1.5%	$1.15B+1.0%	$1.14B-1.1%	$1.15B-7.5%
Total Carrying Value of Debt	——	——	——	——
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	48.5M+1.7%	47.6M+9.2%	43.6M+0.5%	43.4M-5.4%
Common Stock Shares Outstanding	——	$8.9M-36.9%	$14.1M—	——
Additional paid-in capital	$1.92B+10.7%	$1.74B+8.3%	$1.6B+0.3%	$1.6B+0.5%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$483K+5.7%	$457K+5.3%	$434K0.0%	$434K-5.4%
Number of Exercisable Options	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	1.1M-20.6%	1.4M-42.1%	2.4M+10.4%	2.2M+34.1%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Share Repurchase Authorization Limit	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$66.39-6.6%	$71.06+3.3%	$68.80-3.1%	$70.97-9.1%
Cumulative Cost Basis	$3.3B+11.6%	$2.95B+6.2%	$2.78B+1.8%	$2.73B-5.7%
Guarantor Obligations - Maximum Exposure	——	——	——	——
Indemnification Liability Maximum Exposure	——	——	——	——
Operating Lease Income - 2023 (Lessor)	——	——	——	——
Operating Lease Income - 2024 (Lessor)	——	——	——	——
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$100M0.0%	$100M0.0%	$100M0.0%	$100M0.0%
Common stock, shares issued (in shares)	$48.46M+1.7%	$47.64M+9.2%	$43.62M+0.5%	$43.39M-5.4%
Common Stock, Shares, Outstanding	$48.3M+5.7%	$45.69M+5.2%	$43.41M0.0%	$43.39M-5.4%
Construction work in progress	$18.21M+72.4%	$10.57M+78.7%	$5.91M+76.4%	$3.35M+616%
Contingent funding commitment	——	——	——	——
Long-term debt, gross	——	——	——	——
Less: net unamortized discount	——	——	——	——
Unrecognized compensation cost related to non-vested awards	——	——	——	——
Escrow deposit	$6.21M0.0%	$6.21M0.0%	$6.21M0.0%	$6.21M—
Effective adjustment rate	——	——	——	——
Accrued interest receivable	——	——	——	——
Value of financial guarantee (up to)	——	——	——	——
Incentive To Lessee	$4.98M-36.8%	$7.88M-26.2%	$10.67M+234%	$3.19M—
Remainder of fiscal 2026	——	——	——	——
Amount outstanding under the credit facility	$204M-38.4%	$331.2M+35.2%	$245M+483%	$42M—
Remainder of 2026	——	——	——	——
Development commitments for construction and renovation	——	——	——	——
Noncontrolling interests in subsidiaries	$8.17M-8.4%	$8.91M-14.6%	$10.44M+5.9%	$9.86M-0.4%
Number of board of directors	——	——	——	——
Off-Balance-Sheet, Credit Loss, Liability	——	——	——	——
Increase rate in amount of loss from a default	——	——	——	——
Redeemable noncontrolling interests in subsidiaries	$10.2M+4.1%	$9.79M+1.4%	$9.66M-1.7%	$9.83M—
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$1.12M-20.6%	$1.42M-42.1%	$2.45M+10.4%	$2.22M+34.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$66.39-6.6%	$71.06+3.3%	$68.8-3.1%	$70.97-9.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	$8.9M-36.9%	$14.1M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Amount expected to be recognized	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——
Unamortized Debt Issuance Expense	$9.84M+9.2%	$9.02M+1.2%	$8.91M+4.4%	$8.54M+37.0%
Number of mezzanine loans	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Sublease Income - Thereafter	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does National Health Investors's balance sheet data come from?: Every line is extracted from National Health Investors's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.